Roche v. Promega
This article was originally published in The Gray Sheet
Executive SummaryHoffmann-LaRoche and Roche Molecular Systems face trial in San Francisco federal court on claims that their patents for Taq DNA polymerase were obtained through fraud. If the court rules against Roche, the firm "stands to lose control not only over its Taq patents but may lose its critical [polymerase chain reaction] patents as well," Promega says. In 1996, the court ruled that Cetus, the inventor of the Taq patent, made some material omissions in its application to the U.S. Patent Office ("The Gray Sheet" Aug. 19, 1996, I&W-7)
You may also be interested in...
The FDA’s OPQ touts approval of sixth and seventh continuously manufactured drugs and quicker delivery of inspection results in latest annual report.
No device-related warning letters were released by the US FDA the week of 19 February.
Complex generics and value added medicines share common challenges on harmonization of regulation, lack of incentives and clarity of guidelines, heard delegates to Medicines for Europe’s Regulatory & Scientific Affairs conference.